Ten-Year Risk of Recall of Novel Spine Devices.

IF 2.6 2区 医学 Q2 CLINICAL NEUROLOGY Spine Pub Date : 2024-11-01 Epub Date: 2024-01-26 DOI:10.1097/BRS.0000000000004939
Brant Ansley, Theodore Koreckij, Abbey Jin, Houssam Bouloussa, An-Lin Cheng, Jonathan Dubin
{"title":"Ten-Year Risk of Recall of Novel Spine Devices.","authors":"Brant Ansley, Theodore Koreckij, Abbey Jin, Houssam Bouloussa, An-Lin Cheng, Jonathan Dubin","doi":"10.1097/BRS.0000000000004939","DOIUrl":null,"url":null,"abstract":"<p><strong>Study design: </strong>Observational epidemiological study.</p><p><strong>Objective: </strong>This study's primary objective was to examine the risk of recall for novel spine devices over time. Secondarily, we sought to analyze interbody fusion and vertebral body replacement (VBR) devices (corpectomy cages) as a risk factor for recall.</p><p><strong>Background: </strong>The recall risk of a novel spine device over time has not been reported. In addition, FDA regulations were lowered for interbody fusion devices to enter the market in 2007. As well, VBR implants were recently approved by the FDA for use in the cervical spine in 2015.</p><p><strong>Materials and methods: </strong>Spine devices cleared between January 1, 2008 and December 31, 2018 were identified from the FDA's 510(k) database. All recall data were collected from the database in January 2021 to provide a 2-year minimum follow-up for a recall to occur. Product labels were used to classify interbody fusion and VBR devices. Cumulative incidence function was conducted to compare the overall risk of recall for FDA-cleared spine devices, and the hazard ratio determined for VBR and all other devices versus interbody implants during the study period.</p><p><strong>Results: </strong>A total of 2384 spine devices were cleared through 510(k) in the study period. The hazard of recall at 5 years was 5.3% (95% CI: 4.4%-6.2%) and 6.5% (95% CI: 5.4%-7.7%) at 10 years. No significant difference in recall risk was identified for interbody fusion and VBR devices.</p><p><strong>Conclusion: </strong>The risk of recall at 5 and 10 years of a novel spine device is about half the 12% rate reported for orthopedic devices in general. Despite lowered FDA regulations for interbody fusion devices and recent approval for VBR device use in the cervical spine, no increased risk of recall was detected. Further research is necessary to explain the reason for the lower risk of recall with spine devices.</p><p><strong>Level of evidence: </strong>4.</p>","PeriodicalId":22193,"journal":{"name":"Spine","volume":" ","pages":"E361-E366"},"PeriodicalIF":2.6000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Spine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/BRS.0000000000004939","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/26 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Study design: Observational epidemiological study.

Objective: This study's primary objective was to examine the risk of recall for novel spine devices over time. Secondarily, we sought to analyze interbody fusion and vertebral body replacement (VBR) devices (corpectomy cages) as a risk factor for recall.

Background: The recall risk of a novel spine device over time has not been reported. In addition, FDA regulations were lowered for interbody fusion devices to enter the market in 2007. As well, VBR implants were recently approved by the FDA for use in the cervical spine in 2015.

Materials and methods: Spine devices cleared between January 1, 2008 and December 31, 2018 were identified from the FDA's 510(k) database. All recall data were collected from the database in January 2021 to provide a 2-year minimum follow-up for a recall to occur. Product labels were used to classify interbody fusion and VBR devices. Cumulative incidence function was conducted to compare the overall risk of recall for FDA-cleared spine devices, and the hazard ratio determined for VBR and all other devices versus interbody implants during the study period.

Results: A total of 2384 spine devices were cleared through 510(k) in the study period. The hazard of recall at 5 years was 5.3% (95% CI: 4.4%-6.2%) and 6.5% (95% CI: 5.4%-7.7%) at 10 years. No significant difference in recall risk was identified for interbody fusion and VBR devices.

Conclusion: The risk of recall at 5 and 10 years of a novel spine device is about half the 12% rate reported for orthopedic devices in general. Despite lowered FDA regulations for interbody fusion devices and recent approval for VBR device use in the cervical spine, no increased risk of recall was detected. Further research is necessary to explain the reason for the lower risk of recall with spine devices.

Level of evidence: 4.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
新型脊柱设备的十年召回风险。
研究设计观察性流行病学研究:本研究的主要目的是研究新型脊柱器械随时间推移的召回风险。其次,我们试图分析作为召回风险因素的椎间融合器和椎体置换(VBR)器械(椎间盘切除套管):背景数据摘要:新型脊柱器械随着时间推移的召回风险尚未见报道。此外,2007 年美国食品及药物管理局降低了椎间融合器械进入市场的规定。此外,VBR 植入物最近于 2015 年获得 FDA 批准用于颈椎:从 FDA 的 510(k) 数据库中确定了 2008 年 1 月 1 日至 2018 年 12 月 31 日期间获得批准的脊柱器械。2021 年 1 月从数据库中收集了所有召回数据,为召回提供了至少 2 年的跟踪时间。产品标签用于对椎间融合器械和 VBR 器械进行分类。通过累积发生率函数来比较 FDA 批准的脊柱器械的总体召回风险,并确定研究期间 VBR 和所有其他器械与椎间融合器械的危险比。5年召回风险为5.3%(95% CI:4.4%-6.2%),10年召回风险为6.5%(95% CI:5.4%-7.7%)。椎间融合器和VBR器械的召回风险无明显差异:结论:新型脊柱器械 5 年和 10 年的召回风险约为一般骨科器械 12% 召回风险的一半。尽管美国食品及药物管理局降低了对椎间融合器械的规定,最近又批准在颈椎中使用 VBR 器械,但并未发现召回风险增加。要解释脊柱器械召回风险较低的原因,还需要进一步的研究:V.
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Spine
Spine 医学-临床神经学
CiteScore
5.90
自引率
6.70%
发文量
361
审稿时长
6.0 months
期刊介绍: Lippincott Williams & Wilkins is a leading international publisher of professional health information for physicians, nurses, specialized clinicians and students. For a complete listing of titles currently published by Lippincott Williams & Wilkins and detailed information about print, online, and other offerings, please visit the LWW Online Store. Recognized internationally as the leading journal in its field, Spine is an international, peer-reviewed, bi-weekly periodical that considers for publication original articles in the field of Spine. It is the leading subspecialty journal for the treatment of spinal disorders. Only original papers are considered for publication with the understanding that they are contributed solely to Spine. The Journal does not publish articles reporting material that has been reported at length elsewhere.
期刊最新文献
Temporal Trends of Improvement After Minimally Invasive Transforaminal Lumbar Interbody Fusion. Intraoperative Hypotension Is an Important Modifiable Risk Factor for Major Complications in Spinal Fusion Surgery. Clinical Outcome of Lumbar Hybrid Surgery in a Consecutive Series of Patients With Long-term Follow-up. Does Paraspinal Muscle Mass Predict Lumbar Lordosis Before and After Decompression for Degenerative Spinal Stenosis? The Utility of the Surgical Apgar Score in Assessing the Risk of Perioperative Complications Following Spinal Fusion Surgery for Pediatric Patients With Scoliosis and Cerebral Palsy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1